China biopharmaceutical: second generation highly selective P2X3 inhibitor approved clinical trial
Financial Associated Press, Dec. 21 - China biopharmaceutical announced on the Hong Kong stock exchange that the company's second-generation highly selective P2X3 inhibitor (tcr1672) has obtained the drug clinical trial approval notice issued by the China food and Drug Administration and agreed to carry out the clinical trial of refractory chronic cough (RCC) in China.
This text is a result of machine translation.
Related companies：
Briefing Aug 01, 2022 03:11 PM
· Healthcare
Biomedical Lab Supplies Producer Acumen Bags 100 Mn of CNY in Series A Round
In-depth
Healthcare
WIM 2022: Transcript of Fireside Chat of Biotech [1/2]
EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript for Fireside Chat of Biotech. Leon Tang, Bing Yuan, Ying Huang, Dahai Guo, and Sally Wang are the five guest speakers in this chat.
Aug 05, 2022 09:11 PM
Apr 26, 2022 12:26 PM
Apr 21, 2022 07:07 PM
Apr 18, 2022 06:30 PM
Jun 29, 2021 11:48 PM
Briefing Jun 28, 2022 04:29 PM
· Healthcare
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
In-depth
Healthcare
WIM 2022: Transcript of Fireside Chat of Biotech [2/2]
EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript for Fireside Chat of Biotech. Leon Tang, Bing Yuan, Ying Huang, Dahai Guo, and Sally Wang are the five guest speakers in this chat.
Aug 05, 2022 09:08 PM
In-depth
Financials
WIM2022: Transcripts of SPAC Panel, Better Way for Chinese Companies to Be Listed
EqualOcean organized the WIM2022 event in New York City during July 29 to July 30, 2022. The following is the transcript for the Panel of SPAC. James Hu and Kevin Chen are the two guest speakers in this panel.
Aug 03, 2022 11:38 PM
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Insight
In-depth
Technology
WIM2022: Transcripts of Blockchain Panel, Brilliant Future With Opportunities
Aug 05, 2022 02:06 AM